| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2-Methoxypyridine-5-boronic acid does not have a defined primary pharmacological target as it is primarily a chemical reagent and synthetic intermediate. In medicinal chemistry, the compound serves as a building block for constructing pyridine-containing drug candidates. The boronic acid functionality enables Suzuki-Miyaura cross-coupling reactions with various aryl and heteroaryl halides. The compound has been specifically utilized in the synthesis of antimalarial 3,5-diarylaminopyridines with oral in vivo activity, suggesting that derivatives target malaria parasites, likely through inhibition of essential parasite enzymes or metabolic pathways. Additionally, its use in synthesizing indole-derived protease-activated receptor 4 antagonists indicates potential applications in thrombotic disease treatment by targeting this receptor involved in platelet activation and thrombosis.
|
|---|---|
| ln Vitro |
In vitro activity of 2-Methoxypyridine-5-boronic acid as a standalone compound is not typically evaluated, as its primary role is as a synthetic intermediate. The compound's biological activity would be assessed through the final drug molecules synthesized from this building block. Derivatives synthesized from this compound have shown antimalarial activity, suggesting that the compound's incorporation into drug candidates can lead to potent inhibition of malaria parasites. The compound's utility in synthesizing protease-activated receptor 4 antagonists also indicates potential activity in modulating platelet function and thrombosis pathways.
|
| ln Vivo |
In vivo activity data for 2-Methoxypyridine-5-boronic acid itself are not available, as the compound is not intended for direct administration as a therapeutic agent. However, the compound has been utilized in the preparation of 3,5-diarylaminopyridines with oral in vivo activity against malaria, demonstrating that drug candidates derived from this building block can achieve oral bioavailability and therapeutic efficacy in animal models. These studies would typically involve oral administration to malaria-infected mice, with assessment of parasitemia reduction and survival rates. The compound's role in drug discovery is to enable the synthesis of such orally active antimalarial agents.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for 2-Methoxypyridine-5-boronic acid are not standard, as the compound is a chemical reagent rather than a drug candidate. If evaluated, typical binding assays might involve radioligand displacement or surface plasmon resonance techniques. For enzyme inhibition studies relevant to antimalarial applications, purified parasite enzymes such as dihydrofolate reductase or other targets would be incubated with drug candidates derived from this building block. However, such studies are more commonly performed on the final pharmaceutical compounds rather than on the intermediate itself. The compound may serve as a reference or control in certain biochemical experiments.
|
| Cell Assay |
Cell-based in vitro experiments using 2-Methoxypyridine-5-boronic acid are not typically performed, as the compound is a research chemical and synthetic intermediate. When used in cell biology research, the compound might be incorporated into larger molecules that are then tested on cultured cell lines. For antimalarial applications, drug candidates derived from this compound would be tested on Plasmodium falciparum cultures in erythrocytes, with assessment of parasite growth inhibition using microscopy or flow cytometry. Standard cell culture protocols would be followed, with appropriate safety precautions for handling infectious materials.
|
| Animal Protocol |
In vivo animal studies are not conducted with 2-Methoxypyridine-5-boronic acid itself, as it is a chemical reagent rather than a therapeutic agent. However, drug candidates synthesized from this building block have been evaluated in animal models. For antimalarial applications, typical protocols involve administration of test compounds via oral gavage to mice infected with Plasmodium berghei or P. yoelii, with assessment of parasitemia, survival, and cure rates. For thrombotic disease applications, appropriate animal models such as ferric chloride-induced arterial thrombosis or pulmonary embolism models would be used. All animal studies must be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Methoxypyridine-5-boronic acid have not been extensively characterized, as the compound is a chemical reagent for research use. However, the compound's utility in preparing orally active antimalarial agents suggests that drug candidates derived from this building block can achieve favorable oral bioavailability. As a small molecule with molecular weight 153 g/mol, the compound is expected to have moderate aqueous solubility, being soluble in water. The methoxy group and boronic acid functionality would influence metabolic pathways. The compound's LogP is estimated to be around 0.5–1.0, indicating moderate hydrophilicity. For drug discovery applications, the pharmacokinetic profile would be optimized at the final drug candidate stage.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-Methoxypyridine-5-boronic acid are limited, as the compound is handled as a research chemical in laboratory environments. Standard safety precautions should be followed, including the use of appropriate personal protective equipment such as gloves, goggles, and lab coats. The compound may cause irritation to skin, eyes, and respiratory tract upon exposure. Inhalation of dust should be avoided, and adequate ventilation should be ensured. The compound should be stored away from strong oxidizing agents, in a cool, dry place with the container kept tightly closed. In case of contact, affected areas should be rinsed with plenty of water. Comprehensive toxicological studies have not been reported for this compound.
|
| Additional Infomation |
2-Methoxypyridine-5-boronic acid is a chemical research tool and synthetic intermediate rather than an approved pharmaceutical drug. Its primary applications are in organic synthesis and drug discovery, where it serves as a versatile building block for Suzuki-Miyaura cross-coupling reactions. The compound has been specifically utilized in the preparation of orally active antimalarial 3,5-diarylaminopyridines and in the synthesis of indole-derived protease-activated receptor 4 antagonists for thrombotic diseases. The compound also finds applications in cosmetics and coatings. No clinical trials or regulatory approvals have been documented for this compound itself as a therapeutic agent. The compound is commercially available as a research-grade chemical with purity typically 95% or higher, supplied for laboratory synthesis and biochemical research.
|
| Molecular Formula |
C6H8BNO3
|
|---|---|
| Molecular Weight |
152.94
|
| Exact Mass |
153.059
|
| CAS # |
163105-89-3
|
| PubChem CID |
2734368
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
313.2±52.0 °C at 760 mmHg
|
| Melting Point |
135-140 °C(lit.)
|
| Flash Point |
143.2±30.7 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.524
|
| LogP |
0.69
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
122
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
B(C1=CN=C(C=C1)OC)(O)O
|
| InChi Key |
DHADXDMPEUWEAS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H8BNO3/c1-11-6-3-2-5(4-8-6)7(9)10/h2-4,9-10H,1H3
|
| Chemical Name |
(6-methoxypyridin-3-yl)boronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5385 mL | 32.6926 mL | 65.3851 mL | |
| 5 mM | 1.3077 mL | 6.5385 mL | 13.0770 mL | |
| 10 mM | 0.6539 mL | 3.2693 mL | 6.5385 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
